NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free ADMA Stock Alerts $6.54 +0.34 (+5.48%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$6.23▼$6.6350-Day Range$5.15▼$6.7452-Week Range$3.06▼$6.76Volume2.75 million shsAverage Volume2.66 million shsMarket Capitalization$1.49 billionP/E RatioN/ADividend YieldN/APrice Target$7.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ADMA Biologics alerts: Email Address ADMA Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside19.7% Upside$7.88 Price TargetShort InterestHealthy3.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 4 Articles This WeekInsider TradingSelling Shares$3.93 M Sold Last QuarterProj. Earnings Growth66.67%From $0.30 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector188th out of 910 stocksBiological Products, Except Diagnostic Industry21st out of 153 stocks 2.6 Analyst's Opinion Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageADMA Biologics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.19% of the outstanding shares of ADMA Biologics have been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 8.76%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADMA. Previous Next 2.0 News and Social Media Coverage News SentimentADMA Biologics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ADMA Biologics this week, compared to 3 articles on an average week.Search InterestOnly 23 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,927,169.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ADMA Biologics are expected to grow by 66.67% in the coming year, from $0.30 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is -50.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is -50.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 10.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About ADMA Biologics Stock (NASDAQ:ADMA)ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Read More ADMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMA Stock News HeadlinesApril 17, 2024 | americanbankingnews.comADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Down 8.8% in MarchApril 16, 2024 | morningstar.comADMA Biologics IncApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 3, 2024 | seekingalpha.comRising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)April 1, 2024 | finance.yahoo.comInvestors in ADMA Biologics (NASDAQ:ADMA) have seen splendid returns of 261% over the past three yearsMarch 27, 2024 | markets.businessinsider.comADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price TargetMarch 26, 2024 | markets.businessinsider.comA Closer Look at 6 Analyst Recommendations For ADMA BiologicsMarch 17, 2024 | investing.comAdma Biologics director Steve Elms sells over $6.3 million in company stockApril 23, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 16, 2024 | finance.yahoo.comADMA Apr 2024 5.000 putMarch 15, 2024 | finance.yahoo.comAdma Biologics (ADMA) Stock Moves -0.5%: What You Should KnowMarch 11, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAMMarch 11, 2024 | globenewswire.comADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®March 5, 2024 | globenewswire.comADMA Biologics to Participate in the Raymond James Institutional Investor ConferenceMarch 1, 2024 | seekingalpha.comADMA Biologics, Inc. (ADMA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comADMA Biologics Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | uk.finance.yahoo.comQ4 2023 ADMA Biologics Inc Earnings CallFebruary 29, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | finanznachrichten.deADMA Biologics, Inc.: ADMA Biologics Announces CFO TransitionFebruary 29, 2024 | finance.yahoo.comADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For ADMA BiologicsFebruary 28, 2024 | msn.comADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93MFebruary 28, 2024 | msn.comADMA Biologics' CFO to step downFebruary 28, 2024 | marketwatch.comADMA Biologics Says CFO Brian Lenz Moving to Consulting RoleFebruary 28, 2024 | finance.yahoo.comADMA Biologics Inc Reports Robust Revenue Growth and Positive Adjusted Net Income for FY 2023February 28, 2024 | globenewswire.comADMA Biologics Announces CFO TransitionFebruary 28, 2024 | globenewswire.comADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateSee More Headlines Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ADMA CUSIPN/A CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees624Year FoundedN/APrice Target and Rating Average Stock Price Target$7.88 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+20.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E Ratio21.80 P/E GrowthN/ANet Income$-28,240,000.00 Net Margins-10.94% Pretax Margin-10.94% Return on Equity0.49% Return on Assets0.21% Debt Debt-to-Equity Ratio1.04 Current Ratio5.16 Quick Ratio1.69 Sales & Book Value Annual Sales$258.21 million Price / Sales5.78 Cash Flow$0.05 per share Price / Cash Flow123.38 Book Value$0.60 per share Price / Book10.90Miscellaneous Outstanding Shares228,220,000Free Float214,755,000Market Cap$1.49 billion OptionableOptionable Beta0.46 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Adam S. Grossman (Age 47)Co-Founder, President, CEO & Director Comp: $1.52MDr. Jerrold B. Grossman D.P.S. (Age 76)Ph.D., Co-Founder & Vice Chairman of the Board Comp: $80kMr. Brian Lenz CPA (Age 52)Executive VP, CFO & GM of ADMA BioCenters Comp: $1.08MMs. Kaitlin Kestenberg (Age 37)COO & Senior VP of Compliance Mr. Drew PantelloVice President of Marketing & Corporate DevelopmentMs. Cindy PetersenExecutive Director of Human ResourcesMr. Skyler BloomSenior Director of Business Development & Corporate StrategyMore ExecutivesKey Competitors4D Molecular TherapeuticsNASDAQ:FDMTAutolus TherapeuticsNASDAQ:AUTLTarsus PharmaceuticalsNASDAQ:TARSInhibrxNASDAQ:INBXTwist BioscienceNASDAQ:TWSTView All CompetitorsInsiders & InstitutionsRaymond James Financial Services Advisors Inc.Bought 28,196 shares on 4/23/2024Ownership: 0.114%PFG Investments LLCBought 291,600 shares on 4/22/2024Ownership: 0.147%Mesirow Financial Investment Management Inc.Sold 18,185 shares on 4/19/2024Ownership: 0.026%Allspring Global Investments Holdings LLCBought 7,463 shares on 4/18/2024Ownership: 0.111%Viewpoint Capital Management LLCBought 2,416 shares on 4/16/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ADMA Stock Analysis - Frequently Asked Questions Should I buy or sell ADMA Biologics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADMA shares. View ADMA analyst ratings or view top-rated stocks. What is ADMA Biologics' stock price target for 2024? 4 brokerages have issued 1 year price targets for ADMA Biologics' shares. Their ADMA share price targets range from $6.00 to $10.00. On average, they expect the company's share price to reach $7.88 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View analysts price targets for ADMA or view top-rated stocks among Wall Street analysts. How have ADMA shares performed in 2024? ADMA Biologics' stock was trading at $4.52 on January 1st, 2024. Since then, ADMA shares have increased by 45.6% and is now trading at $6.58. View the best growth stocks for 2024 here. Are investors shorting ADMA Biologics? ADMA Biologics saw a decline in short interest in March. As of March 31st, there was short interest totaling 7,290,000 shares, a decline of 8.8% from the March 15th total of 7,990,000 shares. Based on an average daily trading volume, of 2,750,000 shares, the short-interest ratio is currently 2.7 days. View ADMA Biologics' Short Interest. When is ADMA Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ADMA earnings forecast. How were ADMA Biologics' earnings last quarter? ADMA Biologics, Inc. (NASDAQ:ADMA) released its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.02 by $0.02. The biotechnology company earned $73.90 million during the quarter, compared to analysts' expectations of $73.50 million. ADMA Biologics had a positive trailing twelve-month return on equity of 0.49% and a negative net margin of 10.94%. What ETFs hold ADMA Biologics' stock? ETFs with the largest weight of ADMA Biologics (NASDAQ:ADMA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Inspire Fidelis Multi Factor ETF (FDLS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS) and First Trust Small Cap Growth AlphaDEX Fund (FYC).iShares Micro-Cap ETF (IWC). What guidance has ADMA Biologics issued on next quarter's earnings? ADMA Biologics updated its FY 2025 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $380.0 million-. What is Adam S. Grossman's approval rating as ADMA Biologics' CEO? 9 employees have rated ADMA Biologics Chief Executive Officer Adam S. Grossman on Glassdoor.com. Adam S. Grossman has an approval rating of 29% among the company's employees. This puts Adam S. Grossman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Matinas BioPharma (MTNB), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Gran Tierra Energy (GTE), Tilly's (TLYS), Bionano Genomics (BNGO), Novan (NOVN), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT). Who are ADMA Biologics' major shareholders? ADMA Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include PFG Investments LLC (0.15%), Raymond James Financial Services Advisors Inc. (0.11%), Allspring Global Investments Holdings LLC (0.11%), First Hawaiian Bank (0.05%), EWG Elevate Inc. (0.04%) and Mesirow Financial Investment Management Inc. (0.03%). Insiders that own company stock include Adam S Grossman, Brian Lenz, Bryant Fong, Jerrold B Grossman, Perceptive Advisors Llc, Steve Elms and Young Kwon. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADMA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
